21 WHAT IS THE MOST COST-EFFECTIVE POSITION OF VEDOLIZUMAB IN THE CURRENT TREATMENT ALGORITHM OF ULCERATIVE COLITIS?

Posted on January 18, 2018 by Gastroenterology Journal

There are limited data guiding providers and payers on the most cost-effective position for vedolizumab (VDZ) in current ulcerative colitis (UC) treatment algorithms.

This entry was posted in News. Bookmark the permalink.